ValuEngine upgraded shares of IMMURON LTD/S (NASDAQ:IMRN) from a hold rating to a buy rating in a report issued on Friday morning, ValuEngine reports.
IMRN opened at $2.84 on Friday. IMMURON LTD/S has a 52 week low of $2.38 and a 52 week high of $10.15. The business has a fifty day simple moving average of $3.17 and a 200-day simple moving average of $5.02.
IMMURON LTD/S Company Profile
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments.
Featured Article: If I purchase shares through a brokerage account, am I the holder of record?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for IMMURON LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.